References
- Marrack P, Kappler JW. How the immune system recognizes the body. Sci Am 1993;269:80–9.
- Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signaling co-stimulates murine T cells and pre-vents induction of anergy in T cell clones. Nature 1992;356: 607–10.
- Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555–9.
- Oliveira-dos-Santos AJ, Ho A, Tada Y, Lafaille JJ, Tonegawa S, Mak TW, Penninger JM. CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis. J Immunol 1999;162: 4490–5.
- Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–65.
- Waterhouse PJ, Penninger M, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985–98.
- Lenschow DJ, Ho SC, Sattar H, Fthee L, Gray G, Nabavi N, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal anti-body treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145–55.
- Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792–5.
- Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165–73.
- Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789–92.
- Milich DR, Linsley PS, Hughes JL, Jones JE. Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model. J Immunol 1994; 153:429–35.
- Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265: 1225–7.
- Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159: 3104–8.
- Dune FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15: 406–11.
- Dune FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328–30.
- Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470–80.
- Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treat-ment prevents the development of lupus-like nephritis in a subset of New Zealand Black X New Zealand White mice. J Immunol 1996;157: 3159–64.
- Daikh DI, Wofsy D. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913–6.
- Cunnane G, Yen B, Cassifer G, Brindis S, Wofsy D, Daikh DI. Effects of combined CTLA4Ig and cyclophosphamide on renal pathology in advanced murine lupus (abstract). Arthritis Rheum 1999;42:5359.
- Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. A phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Ftheumatol 2001;28: 95–101.
- Kalunian KC, Davis J, Merrill JT, Petri M, Buyon J, Ginzler E, et aL Treatment of systemic lupus erythematosus by inhibition of T cell costimulation (abstract). Arthritis Rheum 2000;43: S271.
- Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy By, Goldfarb MT, Goffe BS, et aL CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243–52.